Professor Matthias Edinger and his team examine immunologic mechanisms in allogeneic stem cell transplantation (SCT). They aim to better understand the biology of immune reactions between donor and host after SCT to further improve the safety and efficacy of this treatment modality. In experimental studies they showed that CD4⁺CD25⁺ regulatory T cells (Treg) from the stem cell donor protect from graft-versus-host disease (GvHD) without necessarily abrogating the beneficial graft-versus-leukemia effect (GvL) of conventional donor T cells.